Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition:   Retinitis Pigmentosa Intervention:   Biological: Intravitreal autologous CD34+ cells Sponsors:   University of California, Davis;   Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition:   X-Linked Retinitis Pigmentosa Intervention:   Other: Other: Assessments Sponsor:   NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition:   Retinitis Pigmentosa Intervention:   Biological: Intravitreal autologous CD34+ cells Sponsors:   University of California, Davis;   Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition:   X-Linked Retinitis Pigmentosa Intervention:   Other: Other: Assessments Sponsor:   NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition:   Retinitis Pigmentosa Intervention:   Biological: Intravitreal autologous CD34+ cells Sponsors:   University of California, Davis;   Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Natural History of the Progression of X-Linked Retinitis Pigmentosa
Condition:   X-Linked Retinitis Pigmentosa Intervention:   Other: Other: Assessments Sponsor:   NightstaRx Ltd, a Biogen Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials

Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Condition:   Retinitis Pigmentosa Intervention:   Biological: Intravitreal autologous CD34+ cells Sponsors:   University of California, Davis;   Cures Within Reach Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2021 Category: Research Source Type: clinical trials